If no further symptoms -appear, complete the administration of the xALT. If symptoms reappear, stop infusion and discontinue patient from the study. CTCAE v. 4.0 Grade III or IV allergic reaction (prolonged; recurrence of symptoms following initial improvement; hospitalization indicated for clinical sequelae; life -threatening consequences; urg ent intervention indicated ): -Stop the infusion of xALT and disconnect infusion tubing from patient. Do not inject any remaining DCs -Administer epinephrine (1:10,000) in 3.5 to 5 mL IV boluses (no more than 6 doses). -Administer IV antihistamine (dip henhydramine 1mg/kg (up to 50 mg) IV push). -If wheezing persists: 0.35 mL of inhaled albuterol or other bronchodilators. -Consider methylprednisolone (1 -2mg/kg or 30- 60 mg IV push ), which may prevent recurrent or ongoing reactions. -Anaphylaxis will be treated promptly with standard of care treatment procedures. -Patient must be taken off study. All toxicities should be graded according to the Common Terminology Criteria for Adverse Events (version 4.0). 17.4 Adverse Event Reporting and Documentation 17.4.1 ADVERSE EVENTS An “AE” will be defined as any adverse change from the subject’s pre -treatment baseline condition, including any clinical or laboratory test abnormality that occurs during the course of research after treatment has started. AEs will be categorized and graded in accordance with the NCI CTC (Version 4.0). 17.4.2 SERIOUS ADVERSE EVEN TS A “SAE” will be defined as an undesirable sign, symptom or medical condition which results in any of the following outcomes: 1) fatal or life threatening ; 2) inpatient hospitalization or a prolongation of existing hospitalization; 3) a persistent or significant disability/incapacity; 4) a congenital anomaly or a birth defect and/or; 5) medically significant event such that it may jeopardize the subject, an d may require medical or surgical intervention to prevent one of the outcomes listed above. SAEs which are serious should be reported immediately to the PI, Dr.